Treating Takayasu disease with lung artery involvement
Part of Heart & circulation, Immune system & allergy, Lungs & breathing clinical trials.
This trial studies treatment for people with Takayasu arteritis when it affects the lung arteries. It may help reduce problems caused by narrowed or involved lung arteries.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with Takayasu arteritis (inflammation of large blood vessels).
- Your Takayasu diagnosis includes involvement of your pulmonary (lung) arteries.
- Your lung artery narrowing is from Takayasu disease, not another cause.
- You do not have lung artery narrowing caused by chronic blood clot disease (CTEPH).
- You do do not have lung artery narrowing caused by fibrosing mediastinitis.
- You do not have lung artery narrowing that is present from birth (congenital pulmonary artery stenosis).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at people with Takayasu's arteritis that also affects the lungs' blood vessels. Researchers want to understand the disease's behavior and outcomes over time.
This trial tests whether a procedure called balloon pulmonary angioplasty is safe and effective for people with chronic thromboembolic disease in the lungs, especially when surgery isn’t an option. If you have CTEPH, it may help improve lung blood flow and symptoms.
This study collects information and blood samples (biomarkers) to better understand Takayasu arteritis and how active it is. It may help researchers find tests that support diagnosis and track disease activity.
This trial studies treatment options for people age 14 and older with severe, active Takayasu arteritis causing major circulation problems and organ strain. It may help reduce inflammation and complications when the disease is flaring and difficult to control.
This study collects medical information from patients diagnosed with Takayasu arteritis, a rare disease affecting large blood vessels. By joining, you help researchers better understand this condition and improve care for future patients.
This trial tests whether adding pirfenidone (a drug that reduces scarring) to your usual treatment helps limit blood vessel thickening and scarring in Takayasu arteritis. You must still have some signs of active disease despite being on standard therapy.
Hear when a new Takayasu Arteritis With Pulmonary Artery Involvement trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.